Pulse.

a daily field guide to health research that matters

◆ Console

‹ Thu · 29 Oct 2026
Standard addition

Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling

Baseline tumor DNA levels and early clearance during treatment strongly predicted which prostate-cancer patients would benefit from combination therapy.

This exploratory biomarker analysis nested in a randomized double-blind phase 3 trial examined Talazoparib plus enzalutamide versus placebo plus enzalutamide in metastatic androgen pathway modulator-resistant (castration-resistant) prostate cancer (TALAPRO-2): a biomarker analysis of circulating tumour DNA and cells for prognosis and molecular profiling. Baseline ctDNA burden and early ctDNA or circulating-cell clearance were strongly prognostic for radiographic progression-free survival.

What the study was

Study design
Exploratory biomarker analysis nested in a randomized double-blind phase 3 trial
Population
Men with metastatic androgen-pathway-modulator-resistant prostate cancer
Sample size
805 randomized patients
Category
Genomics/Precision Medicine
Maturity
Validated
Journal
The Lancet. Oncology

Why it surfaced

Exploratory biomarker analysis nested in a randomized double-blind phase 3 trial; Baseline ctDNA burden and early ctDNA or circulating-cell clearance were strongly prognostic for radiographic progression-free survival. Score kept conservative because only the PubMed abstract and metadata were reviewed.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.